tiprankstipranks
Trending News
More News >
InDex Pharmaceuticals Holding AB (SE:FLERIE)
:FLERIE
Advertisement

InDex Pharmaceuticals Holding AB (FLERIE) Stock Statistics & Valuation Metrics

Compare
1 Followers

Total Valuation

InDex Pharmaceuticals Holding AB has a market cap or net worth of €3.35B. The enterprise value is kr2.82B.
Market Cap€3.35B
Enterprise Valuekr2.82B

Share Statistics

InDex Pharmaceuticals Holding AB has 78,066,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,066,410
Owned by Insiders
Owned by Institutions

Financial Efficiency

InDex Pharmaceuticals Holding AB’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -2.64%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-2.64%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee12.50K
Profits Per Employee-28.50M
Employee Count8
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of InDex Pharmaceuticals Holding AB is 0.3. InDex Pharmaceuticals Holding AB’s PEG ratio is 0.18.
PE Ratio0.3
PS Ratio33086.16
PB Ratio0.79
Price to Fair Value0.79
Price to FCF-194.62
Price to Operating Cash Flow-202.60
PEG Ratio0.18

Income Statement

In the last 12 months, InDex Pharmaceuticals Holding AB had revenue of 100.00K and earned -228.00M in profits. Earnings per share was -3.24.
Revenue100.00K
Gross Profit-41.60M
Operating Income-110.80M
Pretax Income-227.90M
Net Income-228.00M
EBITDA-225.90M
Earnings Per Share (EPS)-3.24

Cash Flow

In the last 12 months, operating cash flow was -16.80M and capital expenditures 0.00, giving a free cash flow of -16.80M billion.
Operating Cash Flow-16.80M
Free Cash Flow-16.80M
Free Cash Flow per Share-0.22

Dividends & Yields

InDex Pharmaceuticals Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.03
52-Week Price Change-4.19%
50-Day Moving Average45.11
200-Day Moving Average45.42
Relative Strength Index (RSI)35.17
Average Volume (3m)9.26K

Important Dates

InDex Pharmaceuticals Holding AB upcoming earnings date is Oct 22, 2025, TBA (Confirmed).
Last Earnings DateJul 31, 2025
Next Earnings DateOct 22, 2025
Ex-Dividend Date

Financial Position

InDex Pharmaceuticals Holding AB as a current ratio of 55.39, with Debt / Equity ratio of 0.02%
Current Ratio55.39
Quick Ratio55.39
Debt to Market Cap<0.01
Net Debt to EBITDA3.83
Interest Coverage Ratio-29.16

Taxes

In the past 12 months, InDex Pharmaceuticals Holding AB has paid 100.00K in taxes.
Income Tax100.00K
Effective Tax Rate>-0.01

Enterprise Valuation

InDex Pharmaceuticals Holding AB EV to EBITDA ratio is -10.82, with an EV/FCF ratio of -143.78.
EV to Sales24.44K
EV to EBITDA-10.82
EV to Free Cash Flow-143.78
EV to Operating Cash Flow-143.78

Balance Sheet

InDex Pharmaceuticals Holding AB has €737.30M in cash and marketable securities with €700.00K in debt, giving a net cash position of -€736.60M billion.
Cash & Marketable Securities€737.30M
Total Debt€700.00K
Net Cash-€736.60M
Net Cash Per Share-€9.44
Tangible Book Value Per Share€59.57

Margins

Gross margin is 40.38%, with operating margin of -110800.00%, and net profit margin of -228000.00%.
Gross Margin40.38%
Operating Margin-110800.00%
Pretax Margin-227900.00%
Net Profit Margin-228000.00%
EBITDA Margin-225900.00%
EBIT Margin-226500.00%

Analyst Forecast

The average price target for InDex Pharmaceuticals Holding AB is €42.97, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€42.97
Price Target Upside1.46% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast101.21%
EPS Growth Forecast-102.52%

Scores

Smart ScoreN/A
AI Score47
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis